All News
Steroid injections worsen knee arthritis
d
EurekAlert!
Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease.
Read Article
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
Copays Reduce Adherence to SLE Medications
Dr. Michael Putman ( @EBRheum) reports on abstract 1115 at #ACR22 Convergence in Philadelphia, PA.
https://t.co/VLyMTSLFCf https://t.co/0nOA0b1576
Links:
Dr. John Cush RheumNow ( View Tweet)
Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/6k4Thx4ZSN https://t.co/1TfapVGMoe
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 1207 joints in 55 RA pts shows that Xray progression over 2 yrs is significantly assoc w/ US Power Doppler (OR 2.92), erosions (OR 4.74), but also with Joint tenderness w/o swelling (OR 1.85) ! (Less signif w/ PsA) https://t.co/gue5jt6Xdx https://t.co/vhFBWTgEHW
Links:
Dr. John Cush RheumNow ( View Tweet)
Mayo LUMEN study looked at SLE nephritis incidence betw 1976 -2018, & showed that LN increased over past 4 decades. LN patients have poor outcomes w/ higer rates of ESRD & mortality rates (SMR 6.33); @10 yr survival =70% & 13% ESRD https://t.co/QDDTORSgyZ https://t.co/89ldzxhuMk
Links:
Dr. John Cush RheumNow ( View Tweet)
Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA
Early diagnosis of AxSpA remains a challenge. Strategies to identify patients with suspected inflammatory back pain in the general population is critical.
https://t.co/LsKOOHDOJI https://t.co/NARG61vBSn
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual inhibition of IL17A and IL17F in AxSpA
https://t.co/OvzQnYw7dH https://t.co/qkCsyBofDJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Do different genders experience PsA differently?
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.
Dr. Petryna ( @DrPetryna) weighs in. #ACR22
https://t.co/nPHf2fR6gQ https://t.co/CcO2gwgh3Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Advancing Telehealth in Rheumatology #ACR22
https://t.co/TZL2ZHVTax https://t.co/4Z5Sbvpo23
Links:
Dr. John Cush RheumNow ( View Tweet)
mTORC1 as a Driver of Inflammation in sJIA Connecting Pathogens of sJIA and MAS
Dr. Olga Petryna discusses Abstract 0004 presented at #ACR22
Abstract 0004: mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
https://t.co/XLbchHGG6w https://t.co/h5KArPYrPZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Can you use the BASDAI in Pregnancy?
Dr. Eric Dein ( @ericdeinmd) discusses abstract 0374 presented at #ACR22 Convergence in Philadelphia, PA. Abstract 0374: The BASDAI Index During Pregnancy.
https://t.co/UB8ZGyQ6mz https://t.co/tkr6cOIMD9
Links:
Dr. John Cush RheumNow ( View Tweet)
Vaccine Efficacy in Patients with Seronegative SpA
Vaccine efficacy remains an important topic at #ACR22 given the ongoing COVID-19 health crisis, current influenza season, and recently published 2022 ACR guidelines.
https://t.co/2PHrJYV8Om
Written by Dr. Sims ( @DrCassySims) https://t.co/hUFnPIDzUU
Links:
Dr. John Cush RheumNow ( View Tweet)
Can we accurately capture disease activity in pregnant patients with AS?
Dr. Aurelie Najm ( @AurelieRheumo) discusses Abstract 0374. #ACR22
https://t.co/oafV1BP91X https://t.co/wMelZm5iOj
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar
Dr. Julian Segan ( @JulianSegan) discusses Abstract 1425 at #ACR22
Abstract 1425: Treatment Persistence and Switching Patterns of AMGEVITA® in German Patients with RD
https://t.co/MpNnrqYxGJ https://t.co/Sfi1kxOXLX
Links:
Dr. John Cush RheumNow ( View Tweet)
Fat and bone are never alone: osteoporotic fracture in RA
Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
https://t.co/4IrdQBq1z2 https://t.co/2HySVG1SGY
Links:
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts #ACR22 - SpA Part3
-Opioids and Health Care Utilization in PsA and AS
-Reproductive health in a post-Roe world
-SpA: Novel Therapies, Diagnostic Dilemmas and Depression
-Tapering TNFi in nonradiographic AxSpA
and more
https://t.co/hXPlQaxPWs https://t.co/2SRYS6EOr7
Links:
Dr. John Cush RheumNow ( View Tweet)
How Underweight Women Can Reduce Hip Fracture Risk
https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS
Links:
Dr. John Cush RheumNow ( View Tweet)
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/cpbDnkfUIS https://t.co/xct8dACBAY
Links:
Dr. John Cush RheumNow ( View Tweet)
RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evobrutinib(861) or placebo(271) for ~ 6 mos. No diff in TEAEs or EAIR , 2 deaths (SLE), SIE 2-3/100PY https://t.co/4HOTKuCAUi https://t.co/u7KSD6RN4q
Links:
Dr. John Cush RheumNow ( View Tweet)